Rituximab for refractory evans syndrome and other immune-mediated hematologic diseases

American Journal of Hematology

Volumn 77, Issue 3, 2004, Pages 303-310

  Mantadakis, Elpis ^a   Danilatou, Vassiliki ^a   Stiakaki, Eftichia ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Autoimmune hemolytic anemia; Chronic ITP; Evans syndrome; Rituximab

Indexed keywords

COLD AGGLUTININ; CORTICOSTEROID; CYCLOSPORIN; DIPHENHYDRAMINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; RITUXIMAB; STEROID; VINCRISTINE;

ADULT; ANAPHYLAXIS; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; CASE REPORT; CRYOGLOBULINEMIA; DRUG EFFICACY; DRUG INDICATION; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HEMATOLOGIC DISEASE; HEMOLYSIS; HUMAN; IMMUNE SYSTEM; INFECTION PREVENTION; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PURE RED CELL ANEMIA; RELAPSE; REMISSION; THROMBOCYTOPENIA; WALDENSTROEM MACROGLOBULINEMIA;

ADULT; ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; FOLLOW-UP STUDIES; HUMANS; MALE; PLATELET COUNT; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TIME FACTORS;

EID: 7244247014     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20180     Document Type: Article

References (62)

1. Maloney DG, Grillo-Lopez AJ, et al. IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;6:2188-2195.
2. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-2833.
3. Oyama Y, Papadopoulos EB, Miranda M, Traynor AE, Burt RK. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001;28:903-905.
4. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26(5 Suppl 14):66-73.
5. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-276.
6. Zaja F, Iacona I, Masolini P, et al. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia. Haematologica 2002;87:189-195.
7. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet 2001;358:1511-1513.
8. Zecca M, Nobili B, Ramenghi U, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood 2003;101:3857-3861.
9. Trape G, Fianchi L, Lai M, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Hematologica 2003; 88:223-224.
10. Gupta N, Kavuru S, Patel D, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia 2002;16:2092-2095.
11. Ahrens N, Kingreen D, Seltsam A, Salama A. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244-245.
12. McMahon C, Babu L, Hodgson A, Hayat A, Connell NO, Smith OP. Childhood refractory autoimmune hemolytic anaemia: is there a role for anti-CD20 therapy (rituximab)? Br J Haematol 2002;117: 480-483.
13. Iannitto E, Ammatuna E, Marino C, Cirrincione S, Greco G, Mariani G. Sustained response of refractory chronic lymphocytic leukemia in progression complicated by acute hemolytic anemia to anti-CD20 monoclonal antibody. Blood 2002;99:1096-1097.
14. Ship A, May W, Lucas K. Anti-CD20 monoclonal antibody therapy for autoimmune hemolytic anemia following T cell-depleted, haplo-identical stem-cell transplantation. Bone Marrow Transplant 2002;29:365-366.
15. Perrotta S, Locatelli F, La Manna A, Cennamo L, De Stefano P, Nobili B. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus. Br J Haematol 2002;116:465-467.
16. Seipelt G, Bohme A, Koschmieder S, Hoelzer D. Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome. Ann Hematol 2001;80:170-173.
17. Abdel-Raheem MM, Potti A, Kobrinski N. Severe Evans's syndrome secondary to interleukin-2 therapy: treatment with chimeric monoclonal anti-CD20 antibody. Ann Hematol 2001;80: 543-545.
18. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: immune thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc 2003;78:1340-1346.
19. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001;98: 952-957.
20. Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic thrombocytopenia and neutropenia. Eur J Haematol 2001;66:408-411.
21. Delgado J, Bustos JG, Jimenez-Yuste V, Hernandez-Navarro F. Anti-CD20 monoclonal antibody therapy in refractory immune thrombocytopenic purpura. Haematologica 2002;87:215-216.
22. Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med 2000;133:275-279.
23. Fernandez MJ, Llopis I, Pastor E, Real E, Grau E. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab. Haematologica 2003;88:ELT02.
24. Hegde UP, Wilson WH, White T, Cheson BD. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002;100: 2260-2262.
25. Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukemia. Blood 2002;99:1092-1094.
26. Battle M, Ribera JM, Oriol A, Plensa E, Milla F, Feliu E. Successful response to rituximab in a patient with pure red cell aplasia complicating chronic lymphocytic leukaemia. Br J Haematol 2002; 118:1192-1193.
27. Zecca M, De Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood 2001; 97:3995-3997.
28. Zaja F, Russo D, Fuga G, Patriarca F, Ermacora A, Baccarani M. Rituximab for the treatment of type II mixed cryoglobulinemia. Haematologica 1999;84:1157-1158.
29. Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101: 3827-3834.
30. Berentsen S, Tjonnfjord GE, Brudevold R, et al. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease. Br J Haematol 2001;115:79-83.
31. Mori A, Tamaru J, Sumi H, Kondo H. Beneficial effects of rituximab on primary cold agglutinin disease refractory to conventional therapy. Eur J Haematol 2002;68:243-246.
32. Layios N, Van Den Neste E, Jost E, Deneys V, Scheiff JM, Ferrant A. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia 2001;15:187-188.
33. Gharib M, Poynton C. Complete, long-term remission of refractory idiopathic cold haemagglutinin disease after Mabthera. Br J Haematol 2002;117:248-249.
34. Engelhardt M, Jakob A, Ruter B, Trepel M, Hirsch F, Lubbert M. Severe cold hemagglutinin disease (CHD) successfully treated with rituximab. Blood 2002;100:1922-1923.
35. Cohen Y, Polliack A, Zelig O, Goldfarb A. Monotherapy with rituximab induces rapid remission of recurrent cold agglutinin-mediated hemolytic anemia in a patient with indolent lymphoplasmacytic lymphoma. Leuk Lymphoma 2001;42:1405-1408.
36. Sparling TG, Andricevic M, Wass H. Remission of cold hemagglutinin disease induced by rituximab therapy. Can Med Assoc J (CMAJ/JAMC) 2001;164:1405.
37. Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin's lymphoma. Br J Haematol 2001;112:1085-1086.
38. Morselli M, Luppi M, Potenza L, et al. Mixed warm and cold autoimmune hemolytic anemia: complete recovery after 2 courses of rituximab treatment. Blood 2002;99:3478-3479.
39. Pulik M, Genet P, Lionnet F, Touahri T. Treatment of primary chronic cold agglutinin disease with rituximab: maintenance therapy may improve the results. Br J Haematol 2002;117:998-999.
40. Byrd JC, White CA, Link B, Lucas MS, Velasquez WS, Rosenberg J, et al. Rituximab therapy in Waldenström's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999;10: 1525-1527.
41. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenström's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.
42. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia. Clin Lymphoma 2002;3:163-166.
43. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia. Semin Oncol 2003;30:243-247.
44. Weide R, Heymanns J, Koppler H. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab. Br J Haematol 2000;109:838-841.
45. Liberato B, Riethmuller A, Comenzo RL, Lis E, Raizer JJ. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy. J Neurooncol 2003;63:207-211.
46. Silverman GJ, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003; 48:1484-1492.
47. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69.
48. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000; 96:1184-1186.
49. Song KW, Mollee P, Patterson B, Brien W, Crump M. Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. Br J Haematol 2002;119: 125-127.
50. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 2000;85:894-895.
51. McIlwaine LM, Fitzsimons EJ, Soutar RL. Inappropriate anti-diuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual and fatal triad in a patient 13 months post rituximab and autologous stem-cell transplantation. Clin Lab Haematol 2001;23:253-254.
52. Motto DG, Williams JA, Boxer LA. Rituximab for refractory childhood autoimmune hemolytic anemia. Isr Med Assoc J 2002; 4:1006-1008.
53. Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis 2003;36:47-49.
54. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000.
55. Van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 2002;100:2257-2259.
56. Papadaki T, Stamatopoulos K, Anagnostopoulos A, Fassas A. Rituximab-associated immune myelopathy. Blood 2003;102: 1557-1558.
57. + T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes. Arthritis Rheum 2000;43:834-843.
58. Rose AL, Forsythe AM, Maloney DG. Agranulocytosis unresponsive to growth factors following rituximab in vivo purging. Blood 2003;101:4225-4226.
59. Voog E, Brice P, Cartron J, Muller JY, Lazard E, Galanaud P, Solal-Celigny P. Acute agranulocytosis (AA) in three patients treated with rituximab for non-Hodgkin lymphoma. Blood 2001; 98:4668a (abstract).
60. Mathew P, Chen G, Wang W. Evans syndrome: results of a national survey. J Pediatr Hematol Oncol 1997;19:433-437.
61. Duperier T, Felsher J, Brody F. Laparoscopic splenectomy for Evans syndrome. Surg Laparosc Endosc Percutan Tech 2003;13:45-47.
62. Julia A, Araguas C, Rossello J, et al. Lack of useful clinical predictors of response to splenectomy in patients with chronic idiopathic thrombocytopenic purpura. Br J Haematol 1990;76: 250-255.